Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Umm, yes it will. What happened to hammerlock on the IR market? Whoopsy.
More than 905M stated in last 10Q. Dilution took place between quarter and & filing...again.
This will be the 3rd week straight of fictitious forecasts...
I could be wrong about this, but offhand I don't believe any other ER ADT product claimed oral abuse prevention.
Product has already been approved for ER in October per my earlier post. Seems like strong tech.
In October they received approval for ER ADT of morphine sulfate using both physical & chemical properties that prevents smoking, snorting, injection and oh yeah, ORAL ABUSE.
http://www.prnewswire.com/news-releases/inspirion-delivery-technologies-receives-fda-approval-for-morphabond-morphine-sulfate-extended-release-tablets-cii-an-opioid-analgesic-formulated-with-abuse-deterrent-properties-300153910.html
I never claimed that, but the slam dunk on the other hand many times. LOL
July 2016 slam dunk approval LOL
Mine is much closer to reality.
Or we could have none if he gets behind schedule. Reality swings both ways.
This quarter we will file generic dihydrogen monoxide after a good round of tiddilywinks.
Except lobbyists never go away. Relationships are built that open doors to all levels of government.
CEO has actually addressed this in conference calls and says big pharma wants too much, which is why Elite chooses to take their chances on companies like SunGen (recent startup).
If per the WSJ, only 27% of patients use opiates as prescribed, does this mean Elite's target market has just shrunk 73%?
Which also means he has close relationships developed over the years with big pharma lobbyists.
There are several pharmas based on NJ, but Elite is also one of them.
Meeting with Sheriffs was a complete joke.
Egalet getting Press this morning on FDA approving distribution of Arymo ADT ER properties.
You are correct, but it has everything to do with what actually gets in the hands of patients.
And we know how fast legislation acts. Don't get me wrong, would be great to see Congress come together. How is the new FDA chief coming along? Only been 3 months without a new director.
Funny, no regulation around that. Insurance is just starting to cover ADTs in a few states. Many here act like doctors will be forced to prescribe all ADTs. If that was the case, those already approved would be doing much much better. Not the case.
We are in agreement 100%. My comment was just misinterpreted. Non-ADT would need to convert to any approved ADT product, from Elite or anyone else. Price is part of that equation as well as overall benefit as perceived by doctors. A doctor may simply prescribe ADT to a small number of patients they deem as at risk of abuse.
Quite frankly, no. The non-ADT drugs are selling today. Depends on the benefit & price for a conversion to take place to ADT.
Just trying to paint a real picture. This is no slam dunk. There currently is and will continue to be plenty of competition.
So did Upsher for their NORCO ANDA.
This has zero to do with the initial question.
Look in 10K's. Will have annual compensation section for directors & breakout of payment types.
The dilution has slowed. I think we'll know within 4 months whether the AS will increase. There isn't much of a plan B to raise additional cash. He will want the wiggle room, especially if a large partner doesn't materialize, FDA delays or study/bridging results aren't as expected
Lol nice try. Bending language only goes so far. 6% is HUGE growth. I bet Purdue is quivering. LOL
More or less. Just shows that the wording isn't exact and provides flexibility. May not hear anything this week despite what other's suggest.
Garbage. Here is the script from November:
"We already filed oxy APAP, where we are targeting one more ANDA this quarter and four for next year. The four will average one per quarter."
And hear management blame timing on the last two quarter slowing revenues? Piss poor excuses, plain & simple.
"Near CFP" does not stop additional share dilution.
No, the company did not say otherwise:
NOTE 21. SUBSEQUENT EVENTS
The Company has evaluated subsequent events from the balance sheet date through February 9, 2017, the date the accompanying financial statements were issued. The following are material subsequent events.
Common Stock sold pursuant to the Lincoln Park Purchase Agreement
Subsequent to December, 2016 and up to February 1, 2017 (the latest practicable date), a total of 6,604,914 shares of Common Stock were sold and 48,354 additional commitment shares were issued, pursuant to the Lincoln Park Purchase Agreement. Proceeds received from such transactions totaled $1.0 million.
Might want to also check the definition of sequential. Quarterly revs have fallen sequentially the past few quarters. IR's job is to make the script as positive as possible. Comparing year/year is the ONLY way to make the financials look any bit positive, but this is not sequential. Any introductory investor knows sequential means quarter over quarter.
See the sequential flow of revenues:
Jun '16: $3.3M
Sep '16: $2.7M
Dec '16: $2.3M
That is clearly not sequential growth. Now let's take a look at gross margin for the same time periods:
Jun '16: 34.3%
Sep '16: 29.9%
Dec '16: 25.9%
Again, sequentially these margins are getting hammered. Cherry picking quotes does no good.
In the Q we already see additional dilution after the quarter end date. How can you say there will be no more dilution when facts say otherwise?
Can't afford R&D either. Let's compare the last few quarters of revenue & margins? Are they increasing? Hell no.
They aren't cash flow positive. Look at the financials.
Nasrat did say "on average" of one per quarter so may not see submission next week.
Adding more employees, but can't afford them all yet. Hopefully that will change soon.
I would imagine most OTC stocks aren't legitimate or viable long-term. Remember, Elite was once on the AMEX.